{"id":"https://openalex.org/W2099210971","doi":"https://doi.org/10.1191/135248506ms1318oa","title":"A prospective open-label study of glatiramer acetate: over a decade of continuous use in multiple sclerosis patients","display_name":"A prospective open-label study of glatiramer acetate: over a decade of continuous use in multiple sclerosis patients","alternate_titles":[],"publication_year":2006,"publication_date":"2006-06-01","ids":{"openalex":"https://openalex.org/W2099210971","doi":"https://doi.org/10.1191/135248506ms1318oa","mag":"2099210971","pmid":"https://pubmed.ncbi.nlm.nih.gov/16764344"},"language":"en","primary_location":{"id":"doi:10.1191/135248506ms1318oa","doi":"https://doi.org/10.1191/135248506ms1318oa","is_oa":false,"landing_page_url":"https://doi.org/10.1191/135248506ms1318oa","pdf_url":null,"source":{"id":"https://openalex.org/S136332993","display_name":"Multiple Sclerosis Journal","issn_l":"1352-4585","issn":["1352-4585","1477-0970"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-2","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320017","host_organization_name":"SAGE Publishing","host_organization_lineage":["https://openalex.org/P4310320017"],"host_organization_lineage_names":["SAGE Publishing"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Multiple Sclerosis Journal","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2099210971"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5108224499","display_name":"Corey C. Ford","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"C C Ford","raw_affiliation_strings":["MIND Imaging Center, Albuquerque, NM, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"MIND Imaging Center, Albuquerque, NM, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5037675795","display_name":"K. P. Johnson","orcid":"https://orcid.org/0009-0001-4179-8640","observed_orcids":["https://orcid.org/0009-0001-4179-8640"]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"K P Johnson","raw_affiliation_strings":["Maryland Center for MS, Baltimore, MD, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Maryland Center for MS, Baltimore, MD, USA,","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110223971","display_name":"Robert P. Lisak","orcid":"https://orcid.org/0000-0001-7638-1696","observed_orcids":["https://orcid.org/0000-0001-7638-1696"]},"institutions":[{"id":"https://openalex.org/I185443292","display_name":"Wayne State University","ror":"https://ror.org/01070mq45","country_code":"US","type":"education","lineage":["https://openalex.org/I185443292"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"R P Lisak","raw_affiliation_strings":["Wayne State University, Detroit, MI, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Wayne State University, Detroit, MI, USA","institution_ids":["https://openalex.org/I185443292"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5056460527","display_name":"HILLEL S. PANITCH","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I111236770","display_name":"University of Vermont","ror":"https://ror.org/0155zta11","country_code":"US","type":"education","lineage":["https://openalex.org/I111236770"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"H S Panitch","raw_affiliation_strings":["University of Vermont, Burlington, VT, USA","UNIVERSITY OF VERMONT"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Vermont, Burlington, VT, USA","institution_ids":["https://openalex.org/I111236770"]},{"raw_affiliation_string":"UNIVERSITY OF VERMONT","institution_ids":["https://openalex.org/I111236770"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5089749444","display_name":"Galia Shifroni","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210109720","display_name":"Teva Pharmaceuticals (Israel)","ror":"https://ror.org/01wfv3m53","country_code":"IL","type":"company","lineage":["https://openalex.org/I4210109720"]}],"countries":["IL"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"G Shifroni","raw_affiliation_strings":["Teva Pharmaceutical Industries Ltd., Petah Tiqva, Israel"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Teva Pharmaceutical Industries Ltd., Petah Tiqva, Israel","institution_ids":["https://openalex.org/I4210109720"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5076338840","display_name":"Jerry S. Wolinsky","orcid":"https://orcid.org/0000-0002-8197-2762","observed_orcids":["https://orcid.org/0000-0002-8197-2762"]},"institutions":[{"id":"https://openalex.org/I919571938","display_name":"The University of Texas Health Science Center at Houston","ror":"https://ror.org/03gds6c39","country_code":"US","type":"education","lineage":["https://openalex.org/I919571938"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"J S Wolinsky","raw_affiliation_strings":["University of Texas Health Science Center at Houston, Houston, TX, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Texas Health Science Center at Houston, Houston, TX, USA","institution_ids":["https://openalex.org/I919571938"]}]},{"author_position":"last","author":{"id":null,"display_name":"The Copaxone\u00ae Study Group","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"The Copaxone\u00ae Study Group","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":4,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":4400,"currency":"USD","value_usd":4400},"apc_paid":null,"fwci":11.233,"has_fulltext":false,"cited_by_count":148,"reviewed_by_count":0,"citation_normalized_percentile":{"value":0.98972854,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":86,"max":99},"biblio":{"volume":"12","issue":"3","first_page":"309","last_page":"320"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10137","display_name":"Multiple Sclerosis Research Studies","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Clinical Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10137","display_name":"Multiple Sclerosis Research Studies","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Clinical Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11827","display_name":"Polyomavirus and related diseases","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11735","display_name":"Peripheral Neuropathies and Disorders","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Clinical Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/glatiramer-acetate","display_name":"glatiramer acetate","score":1.0},{"id":"https://openalex.org/keywords/relapsing-remitting-multiple-sclerosis","display_name":"relapsing-remitting multiple sclerosis","score":0.9440000057220459},{"id":"https://openalex.org/keywords/long-term-follow-up","display_name":"long-term follow-up","score":0.8820000290870667},{"id":"https://openalex.org/keywords/relapse-rate","display_name":"relapse rate","score":0.8180000185966492},{"id":"https://openalex.org/keywords/expanded-disability-status-scale","display_name":"Expanded Disability Status Scale","score":0.8450000286102295},{"id":"https://openalex.org/keywords/disability-progression","display_name":"disability progression","score":0.9259999990463257},{"id":"https://openalex.org/keywords/ambulatory-status","display_name":"ambulatory status","score":0.6620000004768372},{"id":"https://openalex.org/keywords/drug-withdrawal","display_name":"drug withdrawal","score":0.47699999809265137},{"id":"https://openalex.org/keywords/disease-modifying-therapy","display_name":"disease-modifying therapy","score":0.7940000295639038}],"concepts":[{"id":"https://openalex.org/C2778577042","wikidata":"https://www.wikidata.org/wiki/Q418274","display_name":"Glatiramer acetate","level":3,"score":0.9258536100387573},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8990790843963623},{"id":"https://openalex.org/C2780640218","wikidata":"https://www.wikidata.org/wiki/Q8277","display_name":"Multiple sclerosis","level":2,"score":0.7511923313140869},{"id":"https://openalex.org/C35785553","wikidata":"https://www.wikidata.org/wiki/Q756720","display_name":"Ambulatory","level":2,"score":0.5951752662658691},{"id":"https://openalex.org/C2780892749","wikidata":"https://www.wikidata.org/wiki/Q929518","display_name":"Expanded Disability Status Scale","level":3,"score":0.5198664665222168},{"id":"https://openalex.org/C188816634","wikidata":"https://www.wikidata.org/wiki/Q2113324","display_name":"Prospective cohort study","level":2,"score":0.443779319524765},{"id":"https://openalex.org/C3020694758","wikidata":"https://www.wikidata.org/wiki/Q42417392","display_name":"Relapsing remitting","level":3,"score":0.4259587228298187},{"id":"https://openalex.org/C187212893","wikidata":"https://www.wikidata.org/wiki/Q123028","display_name":"Pediatrics","level":1,"score":0.4039587676525116},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.40233251452445984},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.3942130208015442},{"id":"https://openalex.org/C118552586","wikidata":"https://www.wikidata.org/wiki/Q7867","display_name":"Psychiatry","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000068717","descriptor_name":"Glatiramer Acetate","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004185","descriptor_name":"Disability Evaluation","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005500","descriptor_name":"Follow-Up Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007155","descriptor_name":"Immunologic Factors","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D007155","descriptor_name":"Immunologic Factors","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D007166","descriptor_name":"Immunosuppressive Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D007166","descriptor_name":"Immunosuppressive Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010352","descriptor_name":"Patient Dropouts","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010455","descriptor_name":"Peptides","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D010455","descriptor_name":"Peptides","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D011446","descriptor_name":"Prospective Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D013997","descriptor_name":"Time Factors","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D020529","descriptor_name":"Multiple Sclerosis, Relapsing-Remitting","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true}],"locations_count":2,"locations":[{"id":"doi:10.1191/135248506ms1318oa","doi":"https://doi.org/10.1191/135248506ms1318oa","is_oa":false,"landing_page_url":"https://doi.org/10.1191/135248506ms1318oa","pdf_url":null,"source":{"id":"https://openalex.org/S136332993","display_name":"Multiple Sclerosis Journal","issn_l":"1352-4585","issn":["1352-4585","1477-0970"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-2","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320017","host_organization_name":"SAGE Publishing","host_organization_lineage":["https://openalex.org/P4310320017"],"host_organization_lineage_names":["SAGE Publishing"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Multiple Sclerosis Journal","raw_type":"journal-article"},{"id":"pmid:16764344","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/16764344","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Multiple sclerosis (Houndmills, Basingstoke, England)","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[{"id":"https://openalex.org/G7960754321","display_name":null,"funder_award_id":"FD-40005559-01","funder_id":"https://openalex.org/F4320332163","funder_display_name":"U.S. Food and Drug Administration"}],"funders":[{"id":"https://openalex.org/F4320308970","display_name":"Teva Pharmaceutical Industries","ror":"https://ror.org/01wfv3m53"},{"id":"https://openalex.org/F4320332163","display_name":"U.S. Food and Drug Administration","ror":"https://ror.org/034xvzb47"}],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":20,"referenced_works":["https://openalex.org/W1967507425","https://openalex.org/W1978243650","https://openalex.org/W1983757159","https://openalex.org/W2000548391","https://openalex.org/W2005506388","https://openalex.org/W2020047554","https://openalex.org/W2046729196","https://openalex.org/W2057253056","https://openalex.org/W2112165124","https://openalex.org/W2114225021","https://openalex.org/W2117751925","https://openalex.org/W2127671643","https://openalex.org/W2139367012","https://openalex.org/W2156754245","https://openalex.org/W2326826867","https://openalex.org/W2332846030","https://openalex.org/W2404245847","https://openalex.org/W2509277703","https://openalex.org/W2984556666","https://openalex.org/W4234254101"],"related_works":["https://openalex.org/W2058632873","https://openalex.org/W2123038985","https://openalex.org/W1965936322","https://openalex.org/W2323714838","https://openalex.org/W2057253056","https://openalex.org/W4309178948","https://openalex.org/W2096015860","https://openalex.org/W2901824465","https://openalex.org/W4200368282","https://openalex.org/W4283718337"],"abstract_inverted_index":{"A":[0],"decade":[1],"of":[2,26],"continuous":[3],"glatiramer":[4],"acetate":[5],"(GA)":[6],"use":[7],"by":[8],"relapsing":[9],"remitting":[10],"multiple":[11],"sclerosis":[12],"(RRMS)":[13],"patients":[14,28,42,52,65,169,198,209],"was":[15,29,79,117,123],"evaluated":[16,71],"in":[17,57],"this":[18],"ongoing,":[19],"prospective":[20],"study,":[21],"and":[22,82,88,133,136,142,156,158,164,181,184,190],"the":[23],"neurological":[24],"status":[25],"'Withdrawn'":[27],"assessed":[30],"at":[31,170],"a":[32],"10-year":[33,171],"long-term":[34],"follow-up":[35],"(LTFU)":[36],"visit.":[37],"Modified":[38],"intention-to-treat":[39],"(mITT,":[40],"n=232)":[41],"received":[43],">":[44,110],"or":[45,111],"=1":[46],"GA":[47,77,195],"dose":[48],"since":[49],"1991;":[50],"'Ongoing'":[51],"(n":[53],"=":[54,112],"108)":[55],"continued":[56],"November":[58],"2003.":[59],"Of":[60],"124":[61],"patients,":[62,90,147],"50":[63,183],"Withdrawn":[64,168,208],"returned":[66],"for":[67,85],"LTFU.":[68],"Patients":[69],"were":[70,154,179],"every":[72],"six":[73],"months":[74],"(EDSS).":[75],"Mean":[76],"exposure":[78],"6.99,":[80],"10.1":[81],"4.26":[83],"years":[84],"mITT,":[86],"Ongoing,":[87],"Withdrawn/LTFU":[89],"respectively.":[91,144,166,192],"While":[92,193],"on":[93,194],"GA,":[94],"mITT":[95],"relapse":[96],"rates":[97],"declined":[98],"from":[99],"1.18/year":[100],"prestudy":[101],"to":[102,109],"approximately":[103],"1":[104,113],"relapse/5":[105],"years;":[106,119],"median":[107],"time":[108],"EDSS":[114,121,131,139,148,161,173,187],"point":[115],"increase":[116],"8.8":[118],"mean":[120],"change":[122],"0.73":[124],"+/-":[125,151,176],"1.66":[126],"points;":[127],"58%":[128],"had":[129,210],"stable/improved":[130],"scores;":[132],"24,":[134],"11":[135],"3%":[137],"reached":[138,160,186],"4,":[140,162,188],"6":[141,163,189],"8,":[143,165,191],"For":[145,167],"Ongoing":[146,214],"increased":[149,174],"0.50":[150],"1.65;":[152],"62%":[153],"stable/improved;":[155,180],"24,8":[157],"1%":[159],"LTFU,":[172,207],"2.24":[175],"1.86;":[177],"28%":[178],"68,":[182],"10%":[185],"nearly":[196],"all":[197],"(mean":[199],"disease":[200],"duration":[201],"15":[202],"years)":[203],"remained":[204],"ambulatory.":[205],"At":[206],"greater":[211],"disability":[212],"than":[213],"patients.":[215]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2099210971","counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":1},{"year":2024,"cited_by_count":1},{"year":2023,"cited_by_count":2},{"year":2022,"cited_by_count":4},{"year":2021,"cited_by_count":2},{"year":2020,"cited_by_count":4},{"year":2019,"cited_by_count":5},{"year":2018,"cited_by_count":5},{"year":2017,"cited_by_count":4},{"year":2016,"cited_by_count":8},{"year":2015,"cited_by_count":1},{"year":2014,"cited_by_count":4},{"year":2013,"cited_by_count":5},{"year":2012,"cited_by_count":10}],"updated_date":"2026-11-21T10:27:49.728292","created_date":"2016-06-24T00:00:00"}
